Cargando…

Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report

We report 4 chinese patients with hepatitis B e antigen-positive chronic hepatitis B achieving clearance of HBsAg by using pegylated interferon alpha-2a for less than 1 year, to provide one clinical clue for the treatment of chronic hepatitis B.

Detalles Bibliográficos
Autores principales:	Yang, Jin, Zhao, Lian-san
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714489/ https://www.ncbi.nlm.nih.gov/pubmed/19583877 http://dx.doi.org/10.1186/1743-422X-6-97

Ejemplares similares

Clinical cure rate of inactive HBsAg carriers with HBsAg <200 IU/ml treated with pegylated interferon
por: Li, Hong, et al.
Publicado: (2022)

The potential effect of HBV vaccination on off-treatment HBsAg reversion after interferon-induced HBsAg clearance
por: Jiang, Shaowen, et al.
Publicado: (2023)

Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

Performance Evaluation of an Improved HBsAg Assay (HBsAg NEXT) for the Detection of HBsAg Levels
por: Gupta, Ekta, et al.
Publicado: (2023)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
por: Yan, Lei, et al.
Publicado: (2018)

Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis
por: Song, Aixin, et al.
Publicado: (2021)

Pretreatment microRNA levels can predict HBsAg clearance in CHB patients treated with pegylated interferon α-2a
por: Yang, Yanlin, et al.
Publicado: (2018)

Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure
por: Chen, Qing, et al.
Publicado: (2019)

HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study
por: Al Ashgar, Hamad, et al.
Publicado: (2017)

Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B
por: Li, Hu, et al.
Publicado: (2018)

Comparison of the Clinical Features of Hepatitis A between HBsAg-Positive and HBsAg-Negative Patients
por: Kim, Kwang Min, et al.
Publicado: (2011)

Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBV
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Low serum hyaluronic acid levels associated with spontaneous HBsAg clearance
por: Harkisoen, S., et al.
Publicado: (2015)

Serum IL-5 levels predict HBsAg seroclearance in patients treated with Nucleos(t)ide analogues combined with pegylated interferon
por: Wang, Peipei, et al.
Publicado: (2023)

Comparative analysis of the safety and efficacy of HBsAg-1018 versus HBsAg-Eng: a meta-analysis
por: ZHANG, LIN L., et al.
Publicado: (2020)

B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy
por: Cao, Zhenhuan, et al.
Publicado: (2020)

What are the causes and outcomes of the coexistence of HBsAg and anti-HBs?
por: Afyon, Murat
Publicado: (2016)

Circulating immune complexes and mutations of HBsAg are associated with the undetectable HBsAg in anti-HBs and HBeAg positive occult hepatitis B virus infection
por: Yan, Ying, et al.
Publicado: (2022)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Long-term outcomes of HBsAg/anti-HBs double-positive versus HBsAg single-positive patients with chronic hepatitis B
por: Kwak, Min-Sun, et al.
Publicado: (2019)

Clinical Outcomes of Delayed Clearance of Serum HBsAg in Patients with Chronic HBV Infection
por: Nam, Soon Woo, et al.
Publicado: (2007)

Comparison of Serum HBsAg Quantitation by Four Immunoassays, and Relationships of HBsAg Level with HBV Replication and HBV Genotypes
por: Tuaillon, Edouard, et al.
Publicado: (2012)

Assessment of noninvasive liver stiffness in inactive HBsAg carriers by transient elastography: Fibroscan in inactive HBsAg carriers
por: Sporea, Ioan, et al.
Publicado: (2011)

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro
por: Salpini, Romina, et al.
Publicado: (2017)

Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation
por: Xie, Yandi, et al.
Publicado: (2023)

Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups
por: Ning, Jing, et al.
Publicado: (2022)

AUSTRALIA ANTIGEN (HBsAG) IN INSTITUTIONALISED SCHIZOPHRENICS
por: Chaudhury, S., et al.
Publicado: (1993)

HBsAg seroprevalence among Senegalese militaries
por: Ndiaye, Abdoul A, et al.
Publicado: (2015)

Accuracy Validation of the Elecsys HBsAg II Quant Assay and Its Utility in Resolving Equivocal Qualitative HBsAg Results
por: Lee, Jaehyeon, et al.
Publicado: (2023)

Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg
por: Yang, Xiaoan, et al.
Publicado: (2022)

HBsAg protein composition and clinical outcomes in chronic hepatitis D and variations across HBeAg-negative chronic HBsAg carriers
por: Roade, Luisa, et al.
Publicado: (2023)

Immune-Regulatory Events in the Clearance of HBsAg in Chronic Hepatitis B: Focuses on HLA-DP
por: Mohamadkhani, Ashraf, et al.
Publicado: (2015)

Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection
por: Gantner, Pierre, et al.
Publicado: (2019)

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients
por: Wang, Wen-Xin, et al.
Publicado: (2022)

Frequency of Detectable HBsAg in Fluid Adherent to the Endoscope, Gastric Juice, and Saliva Collected during Endoscopy in Patients Positive for HBsAg
por: Yang, Ung-Suk, et al.
Publicado: (1986)

Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
por: Seto, Wai-Kay, et al.
Publicado: (2012)

Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients
por: Li, Minghui, et al.
Publicado: (2022)

Detection of S-HBsAg Mutations in Patients with Hematologic Malignancies
por: Konopleva, Maria V., et al.
Publicado: (2021)

Evaluation of HBsAg Seroclearance in Patients with Hepatitis B
por: Taşkın, Mehmet Can, et al.
Publicado: (2022)

Prediction of conformational changes by single mutation in the hepatitis B virus surface antigen (HBsAg) identified in HBsAg-negative blood donors
por: Ie, Susan I, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ras3e4rpel4rq1j3gbh96ddnoo